Insmed, Inc. (INSM)
141.47
-2.99
(-2.07%)
USD |
NASDAQ |
Nov 20, 16:00
143.00
+1.53
(+1.08%)
After-Hours: 19:22
Insmed Gross Profit (TTM) : 1.272B for Sept. 30, 2026
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 1.272B |
| June 30, 2026 | 941.78M |
| March 31, 2026 | 663.66M |
| December 31, 2025 | 477.48M |
| September 30, 2025 | 336.83M |
| June 30, 2025 | 296.38M |
| March 31, 2025 | 286.42M |
| December 31, 2024 | 272.91M |
| September 30, 2024 | 259.87M |
| June 30, 2024 | 249.98M |
| March 31, 2024 | 241.24M |
| December 31, 2023 | 234.58M |
| September 30, 2023 | 215.56M |
| June 30, 2023 | 207.46M |
| March 31, 2023 | 195.65M |
| December 31, 2022 | 185.18M |
| September 30, 2022 | 181.79M |
| June 30, 2022 | 164.10M |
| March 31, 2022 | 149.80M |
| December 31, 2021 | 139.26M |
| September 30, 2021 | 126.98M |
| June 30, 2021 | 123.44M |
| March 31, 2021 | 121.47M |
| December 31, 2020 | 119.54M |
| September 30, 2020 | 126.00M |
| Date | Value |
|---|---|
| June 30, 2020 | 125.42M |
| March 31, 2020 | 117.93M |
| December 31, 2019 | 107.26M |
| September 30, 2019 | 77.67M |
| June 30, 2019 | 45.52M |
| March 31, 2019 | 20.78M |
| December 31, 2018 | 3.511M |
| September 30, 2018 | -3.385M |
| June 30, 2018 | -3.145M |
| March 31, 2018 | -2.954M |
| December 31, 2017 | -2.901M |
| September 30, 2017 | -2.85M |
| June 30, 2017 | -2.81M |
| March 31, 2017 | -2.64M |
| December 31, 2016 | -2.438M |
| September 30, 2016 | -2.396M |
| June 30, 2016 | -2.185M |
| March 31, 2016 | -2.064M |
| December 31, 2015 | -1.982M |
| September 30, 2015 | -1.718M |
| June 30, 2015 | -1.61M |
| March 31, 2015 | -1.338M |
| December 31, 2014 | -1.073M |
| September 30, 2014 | -0.902M |
| June 30, 2014 | -0.547M |
Gross Profit Definition
Annual, Interim and Preliminary Items - Commercial, Other Financial Companies
Gross Profit (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 3.874B |
| Gilead Sciences, Inc. | 24.85B |
| Incyte Corp. | 5.502B |
| Madrigal Pharmaceuticals, Inc. | 1.297B |
| Vertex Pharmaceuticals, Inc. | 11.15B |